British pharmaceutical giant AstraZeneca on Friday announced plans to invest $2.5 billion in China, despite the detention there of its former head of operations over alleged illegal activity.
The investment over the next five years will fund the company鈥檚 sixth global strategic research and development centre and grow its Beijing workforce to 1,700 employees, AstraZeneca said in a statement.
<